Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19732583.
- Also identified by DOI 10.1016/j.jpeds.2009.01.074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.
Medical subject headings
- Adverse Drug Reaction Reporting Systems
- Mandelic Acids
- Muscarinic Antagonists
- Nervous System Diseases